Intranasal COVID-19 vaccine candidate shows sterilizing immunity in preclinical tests
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
11 May 2021Study: Long-term benefits of mindfulness intervention to reduce stress, burnout
11 May 2021Intranasal COVID-19 vaccine candidate shows sterilizing immunity in preclinical tests
University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate—AdCOVID—that was created by Altimmune Inc., a Maryland-based clinical-stage biopharmaceutical company.
